eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


1/2021
vol. 20
 
Share:
Share:
abstract:
Review paper

Hormonal replacement therapy in women with a history of internal genital organ malignancy

Maria Brzozowska
1, 2
,
Andrzej Lewiński
1, 2

  1. Department of Endocrinology and Metabolic Diseases, Medical University, Lodz, Poland
  2. Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
Menopause Rev 2021; 20(1): 34-39
Online publish date: 2021/03/18
View full text Get citation
 
PlumX metrics:
Sudden cessation of ovary activity as a result of bilateral oophorectomy or chemo- or radiotherapy in premenopausal women is linked with more serious consequences that bear no comparison to natural menopause – to name just a few: higher rate of mortality, higher rate of colorectal and lung cancer, circulatory system diseases, cognitive disorders, Parkinson’s disease, psychological disorders, osteoporosis, and sexual disorders. The prolonged period of estrogens deficit in premenopausal age is connected with worsened quality of life.

The progress in oncological care means that in many malignant diseases, also in the case of gynaecological malignancies, the percentage of survivors increases. This makes improving the quality of life more and more important.

The purpose of this review is to establish, based on EBM data, the answer to whether replacement hormonal therapy, being the most effective treatment of menopause symptoms, can be recommended for women who have undergone bilateral oophorectomy because of gynaecological cancer.

On the basis of collected data, derived from meta-analysis, and studies which have been published within the last 20 years, it seems that the use of the appropriate type of hormonal replacement therapy (HRT) in properly selected gynaecological cancer survivors (epithelial ovarian cancer – EOC, endometrial cancer, squamous cell carcinoma of the cervix) is safe and effective.

It seems that benefits connected with better quality of life that stem from the use of appropriate HRT in gynaecological cancer survivors predominate the unfounded fear of disease recurrence in selected patients’ groups.
keywords:

hormonal replacement therapy, menopause, gynaecological cancer survivors

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.